← Back to Search

Liposomal Bupivacaine Block for Postoperative Pain

Phase 4
Recruiting
Research Sponsored by Baylor Research Institute
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up during surgery
Awards & highlights

Study Summary

The purpose of this study is to find out what effects (good and bad) that the study medicine called "liposomal bupivacaine" has on subjects that are undergoing a sternotomy. Liposomal bupivacaine solution, is a drug that the doctor will inject before they make the cut through patient's breastbone (sternotomy). Normally pain medicine like this is given right before the surgeon closes up the patient's breastbone, at the end of the surgery. For this study, they want to see if giving the medicine before they make the cut into the patient's breastbone helps their pain. They also want to find out if patients feel less pain after surgery with the study drug than they do with saline and possibly decrease the need for pain medicine. Subjects will be in the study for about 72 hours or until they are discharged from the hospital.

Eligible Conditions
  • Postoperative Pain
  • Blockage
  • Cardiac Surgery

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 72 hours post-op
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 72 hours post-op for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Pain
Postoperative opioid measured in Milligram Morphine Equivalent (MME)
Secondary outcome measures
Intraoperative opioid usage measured in Milligram Morphine Equivalent (MME)

Trial Design

2Treatment groups
Active Control
Placebo Group
Group I: Liposomal Bupivacaine BlockActive Control1 Intervention
Liposomal Bupivacaine (1.3%) solution (20 mL dose). This solution has demonstrated increased efficacy in prolonged analgesia following injection. This solution will be injected as an ultrasound-guided subpectoral interfacial plane block.
Group II: Saline BlockPlacebo Group1 Intervention
Normal saline (0.9%) will be used as the control solution for patients not receiving the liposomal bupivacaine solution. Injection procedure of this solution will be identical to that of the liposomal bupivacaine solution.

Find a Location

Who is running the clinical trial?

Baylor Research InstituteLead Sponsor
199 Previous Clinical Trials
203,096 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
~19 spots leftby Apr 2025